LARYNGOTRACHEAL ANESTHESIA KIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LARYNGOTRACHEAL ANESTHESIA KIT (LARYNGOTRACHEAL ANESTHESIA KIT).
Lidocaine and tetracaine are sodium channel blockers, inhibiting nerve impulse conduction, providing local anesthesia. Epinephrine is a vasoconstrictor that reduces systemic absorption and prolongs duration.
| Metabolism | Lidocaine primarily metabolized by CYP3A4, to a lesser extent CYP1A2; tetracaine hydrolyzed by plasma esterases; epinephrine metabolized by MAO and COMT. |
| Excretion | Renal excretion of lidocaine and its metabolites (primarily monoethylglycinexylidide (MEGX) and glycinexylidide (GX)); <10% unchanged. Biliary/fecal excretion minimal (<5%). |
| Half-life | Lidocaine terminal half-life: 1.5–2 hours (normal hepatic function); prolonged to 3–5 hours in heart failure or hepatic disease. Tetracaine: 2–3 hours. |
| Protein binding | Lidocaine: 60–80% bound primarily to alpha-1-acid glycoprotein (AAG); tetracaine: >90% bound to albumin and lipoproteins. |
| Volume of Distribution | Lidocaine: Vd = 1.1–2.2 L/kg (highly distributed to tissues, especially brain and heart). Tetracaine: Vd = 3–4 L/kg. |
| Bioavailability | Topical: lidocaine 100% (mucosal), tetracaine 100% (mucosal). Oral: not applicable due to high first-pass metabolism. |
| Onset of Action | Topical (larynx/trachea): lidocaine 1–2 min, tetracaine 2–5 min. |
| Duration of Action | Lidocaine: 30–60 min (topical), tetracaine: 60–90 min. Note: Duration shorter in inflamed mucosa; epinephrine may prolong. |
| Molecular Weight | Lidocaine: 234.34 Da; Tetracaine: 264.36 Da (as free base) |
4 mL of 4% lidocaine (160 mg) via atomizer or nebulizer for topical laryngotracheal anesthesia, with additional 2 mL aliquots as needed, not to exceed 4.5 mg/kg total dose.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for lidocaine, which undergoes primarily hepatic metabolism; however, caution in end-stage renal disease (eGFR <15 mL/min) due to potential accumulation of metabolites. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: contraindicated or use only with extreme caution and reduced dose (e.g., maximum 70 mg total). |
| Pediatric use | Weight-based: 1-2 mg/kg (0.25-0.5 mL/kg of 4% solution) of 4% lidocaine via nebulization or atomization, not to exceed 4.5 mg/kg total; maximum 160 mg per dose. |
| Geriatric use | Elderly patients may require dose reduction due to decreased hepatic clearance; initiate at lowest effective dose (e.g., 2-3 mL of 4% lidocaine) and monitor for toxicity. |
| 1st trimester | Limited data; avoid unless benefit outweighs risk. Systemic absorption of lidocaine may occur. |
| 2nd trimester | Use if clearly needed; potential for fetal bradycardia with high doses. |
| 3rd trimester | Use with caution near term; may cause neonatal depression or methemoglobinemia. |
Clinical note
Comprehensive clinical and safety monograph for LARYNGOTRACHEAL ANESTHESIA KIT (LARYNGOTRACHEAL ANESTHESIA KIT).
| Placental transfer | Lidocaine and tetracaine cross the placenta. Fetal plasma levels are 50-60% of maternal levels. |
| Breastfeeding | Lidocaine and tetracaine are excreted in breast milk in low amounts; unlikely to affect infant. Use caution with excessive doses or repeated applications. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to ester-type anesthetics (tetracaine) or amide-type (lidocaine)Severe hypotensionComplete heart block (for lidocaine)Myasthenia gravis (relative)
| Precautions | Risk of systemic toxicity if applied to broken skin or mucous membranes; caution in patients with cardiac disease, hypertension, or hyperthyroidism; avoid use in patients with severe hypotension or shock; use smallest dose needed. |
| Food/Dietary | Avoid eating or drinking for at least 1 hour before and after application to prevent aspiration or choking due to loss of protective airway reflexes. Avoid hot foods or liquids while numbness persists to prevent thermal injury. |
Loading safety data…
| L2 (Probably Compatible) |
| Teratogenic Risk | Lidocaine and tetracaine are local anesthetics with low systemic absorption when applied topically. Lidocaine crosses the placenta, but at doses used for topical anesthesia, fetal concentrations are minimal. Tetracaine has limited data. In first trimester, theoretical risk of teratogenicity is negligible at clinical doses; however, avoid if possible. Second and third trimesters: No known fetal harm with topical use. High doses or inadvertent intravascular injection could cause maternal toxicity and fetal bradycardia. |
| Fetal Monitoring | No specific monitoring required for topical application. If large amounts are used on disrupted mucosa or if inadvertent intravascular injection occurs, monitor for maternal CNS and cardiovascular toxicity (seizures, arrhythmias) and fetal bradycardia. Ensure emergency equipment available. |
| Fertility Effects | No known adverse effects on fertility. Lidocaine and tetracaine are not associated with reproductive toxicity. Topical use has no systemic hormonal impact. |
| Clinical Pearls |
| Laryngotracheal anesthesia kits typically contain lidocaine or similar local anesthetics for topical application to the airway. Administer via atomizer or spray; wait 2-3 minutes after application for optimal anesthesia. Avoid overapplication to prevent systemic toxicity. Use in combination with benzodiazepine sedation for patient comfort during awake intubation. Monitor for signs of lidocaine toxicity (perioral numbness, tinnitus, seizures) especially in patients with hepatic impairment or low cardiac output. Do not use in patients with known allergy to amide anesthetics. Consider using methemoglobinemia risk with prilocaine-containing kits. |
| Patient Advice | You will receive a numbing spray or solution applied to your throat and voice box to prevent discomfort during the procedure. · You may feel a brief stinging or burning sensation initially, followed by numbness. Do not eat or drink until the numbness wears off to avoid choking. · The numbness typically lasts 30 to 60 minutes. Avoid hot foods or beverages during this time to prevent burns. · If you experience ringing in your ears, dizziness, or a metallic taste, alert the healthcare provider immediately. · Do not drive or operate machinery after the procedure due to possible sedation effects. |